---
figid: PMC8411238__gr6
figtitle: Combined metformin-salicylate treatment provides improved anti-tumor activity
  and enhanced radiotherapy response in prostate cancer; drug synergy at clinically
  relevant doses
organisms:
- NA
pmcid: PMC8411238
filename: gr6.jpg
figlink: /pmc/articles/PMC8411238/figure/fig0006/
number: F6
caption: Model of the mechanism of action of metformin (MET) and salicylate (SAL)
  in combination with radiotherapy. The results of this work suggest that MET and
  SAL block mitochondria OxPhos, reduce oxygen consumption and increase extracellular
  acidification leading to activation of AMPK and induction of downstream pathways.
  The MET + SAL combination suppresses more effectively lipogenesis and the Raptor-mTOR
  pathway, mediating an effective blockade of the protein synthesis regulators p70s6k
  and 4EBP1 and elimination of HIF1α levels. MET + SAL synergize with radiotherapy
  to provide improved suppression of tumor growth. Created with BioRender.com.
papertitle: Combined metformin-salicylate treatment provides improved anti-tumor activity
  and enhanced radiotherapy response in prostate cancer; drug synergy at clinically
  relevant doses.
reftext: Evangelia E. Tsakiridis, et al. Transl Oncol. 2021 Nov;14(11):101209.
year: '2021'
doi: 10.1016/j.tranon.2021.101209
journal_title: Translational Oncology
journal_nlm_ta: Transl Oncol
publisher_name: Neoplasia Press
keywords: AMPK | Lipogenesis | mTOR | HIF1a | Histone-H3 | Xenografts | PrCa, prostate
  cancer | MET, metformin | SAL, salicylate | MET + SAL, metformin and salicylate
  used together | RT, radiotherapy / ionizing irradiation with clinical radiotherapy
  units | DNL, de novo lipogenesis | mTOR, the mammalian target of rapamycin | mTORC1,
  mTOR complex 1 | AMPK, AMP-activated protein kinase | LKB1, Liver Kinase B 1 | p70s6k,
  ribosomal p70 S6 kinase | ACC, acetyl-CoA carboxylase | TSC2, Tuberin Sclerosis
  Complex 2 | 4EBP1, Eukaryotic Translation Initiation Factor 4E Binding Protein 1
  | HIF1α, hypoxia inducible factor 1 | OxPhos, oxidative phosphorylation | OCR, oxygen
  consumption rate | ECAR, Extracellular Acidification Rate | P-H3, phosphorylated
  histone H3 | IHC, immunohistochemistry
automl_pathway: 0.9307764
figid_alias: PMC8411238__F6
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8411238__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8411238__gr6.html
  '@type': Dataset
  description: Model of the mechanism of action of metformin (MET) and salicylate
    (SAL) in combination with radiotherapy. The results of this work suggest that
    MET and SAL block mitochondria OxPhos, reduce oxygen consumption and increase
    extracellular acidification leading to activation of AMPK and induction of downstream
    pathways. The MET + SAL combination suppresses more effectively lipogenesis and
    the Raptor-mTOR pathway, mediating an effective blockade of the protein synthesis
    regulators p70s6k and 4EBP1 and elimination of HIF1α levels. MET + SAL synergize
    with radiotherapy to provide improved suppression of tumor growth. Created with
    BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Drl-2
  - ACC
  - tacc
  - acclinal-wing
  - fi
  - anon-70Dc
  - ATPsynbeta
  - Atpalpha
  - adp
  - Amph
  - SNF4Agamma
  - AMPKalpha
  - CycE
  - cyc
  - LanB2
  - anon-70Db
  - tgo
  - sima
  - gig
  - Mtor
  - Tor
  - raptor
  - Thor
  - S6k
  - Pa
  - Con
  - salr
  - salm
  - sala
  - salto
  - sls
  - DNASE2
  - ACACA
  - BMS1
  - ACACB
  - WARS1
  - ATP8A2
  - WDTC1
  - APRT
  - MFAP1
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ARNT
  - HIF1A
  - TSC2
  - MTOR
  - EIF4EBP1
  - RPS6KB1
  - RPS6KB2
---
